Approximately 2-3% of all newly diagnosed cancer in Sweden is H&N cancer and its incidence is estimated to increase by approximately 2% annually (Einhorn et al, 1996). Although tumour sites (larynx, oral cavity, oropharynx, sinus and nose and the salivary glands) are known to affect crucial functions, such as the ability to breath, speak, eat and smell, until recently little has been known about how such impairments impact on the HRQL of H&N cancer patients.The first HRQL studies of H&N cancer patients were crosssectional or retrospective (Pruyn et al, 1986;de Boer et al, 1999), but during the last few years prospective studies have also been published (Jones et al, 1992; List et al, 1996;Deleyiannis et al, 1997;Funk et al, 1997;Hammerlid et al, 1997;Hammerlid et al. 1997; Morton, 1997; Hammerlid et al, 1998; Hammerlid et al, 1998;Bjordal et al, 1999; de Graeff et al, 1999; de Graeff et al, 1999;Deleyiannis et al, 1999; List et al, 1999; Rogers et al, 1999). These studies have been performed with validated questionnaires and have consistently shown that H&N cancer patients' HRQL is significantly below norm values at diagnosis and decreases during and immediately after treatment. During this period, the patients not only have major problems with pain and nutrition but are also limited in daily physical and social functioning. However, within the first year after diagnosis most of these mentioned problems/functions return to their pretreatment values, except symptoms and problems specifically related to treatment, such as xerostomia and reduced taste and smell. On the other hand, mood disorder, especially anxiety, have been found to be less common one year after diagnosis (Hammerlid et al, 1999).In a study published by Funk (Funk et al, 1997), the HRQL of a H&N cancer sample was compared with age-matched, US population norms for the SF-36 (Ware et al, 1993). In this study, it was shown that the H&N cancer patients (particularly the younger ones) scored significantly lower for most on the HRQL domains measured, both at diagnosis and after 6 months.Although the short-term and intermediate effects of H&N cancer and its treatment are well documented, we know very little about the HRQL of H&N cancer survivors more than 12 months after diagnosis. An important question is to what degree they recover normal health status after rehabilitation, i.e. how long-term H&N cancer survivors' health status compares with that of their contemporaries in the general population. A study was therefore performed to examine the HRQL of a large group of H&N cancer survivors 3 years after diagnosis compared with population norms. For this purpose, the generic IQOLA SF-36 Health Survey was chosen with its Altogether 135 H&N cancer patients (mean age 62 years, 31% females) of 151 survivors (89% acceptance) from a longitudinal HRQL study (n = 232) were included 3 years after diagnosis. The H&N cancer patients' SF-36 scores did not differ significantly from those of an age-and sex-matched sample (n = 871) from the Swedish normative population...